Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Results

Cytek Biosciences Misses on EPS, Stock Down 1.72%

Cytek Biosciences reported a loss per share of $0.05, which was worse than expected. The stock reacted negatively, declining by 1.72%. The lack of revenue details and guidance may contribute to investor uncertainty moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.05	N/A	-16.28%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

Cytek Biosciences Misses on EPS, Stock Down 1.72%

Key numbers

Management commentary

Cytek Biosciences, Inc.

More earnings this week

Cytek Biosciences Misses on EPS, Stock Down 1.72%

Key numbers

Management commentary